Featured Publications

Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models

Virtual poster released on Jan 6, 2022
Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery

IMM-1-104: a novel, oral, selective dual-MEK inhibitor that displays broad antitumor activity and high tolerability across RAS and RAF mutant tumors in vivo

Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P252,
Presenter: Brett Hall, Ph.D., Immuneering Chief Scientific Officer

Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model

Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P240
Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery

Transcriptional effects in C26 tumor highlight mechanistic aspects of a novel dual MEK inhibitor, IMM-1-104

Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P254
Presenter: Sarah Kolitz, Ph.D., Immuneering Vice President, Translational Medicine

Publications

Found 13 Results
Page 1 of 2

pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model

Huntington disease (HD), a devastating hereditary neurodegenerative disorder, is caused by an expansion of a CAG trinucleotide repeat that encodes a polyglutamine (polyQ) tract in the huntingtin (HTT) gene.

Journal: Cell Death & Disease


Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse

Huntington Disease (HD) is an incurable autosomal dominant neurodegenerative disorder driven by an expansion repeat giving rise to the mutant huntingtin protein (mHtt), which is known to disrupt a multitude…

Journal: Molecular Neurodegeneration


Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice

Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the…

Journal: JCI Insight


Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.

Copaxone (glatiramer acetate, GA), a structurally and compositionally complex polypeptide nonbiological drug, is an effective treatment for multiple sclerosis, with a well-established favorable safety profile. The short antigenic polypeptide sequences…

Journal: Annals of the New York Academy of Sciences


A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients…

Journal: Genome Medicine


Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.

Multiple sclerosis (MS) is a chronic, progressive, disabling disorder characterized by immune-mediated demyelination, inflammation, and neurodegenerative tissue damage in the central nervous system (CNS), associated with frequent exacerbations and remissions…

Journal: Progress in Neurobiology


The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease

The tri-nucleotide repeat expansion underlying Huntington disease (HD) results in corticostriatal synaptic dysfunction and subsequent neurodegeneration of striatal medium spiny neurons (MSNs). HD is a devastating autosomal dominant disease with…

Journal: Neurobiology of Disease


Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Abstract Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington’s disease. Laquinimod exerts beneficial activities on both the…

Journal: Proceeding of the National Academy of Science


Pridopidine activates neuroprotective pathways impaired in Huntington Disease

Pridopidine has demonstrated improvement in Huntington Disease (HD) motor symptoms as measured by secondary endpoints in clinical trials. Originally described as a dopamine stabilizer, this mechanism is insufficient to explain…

Journal: Human Molecular Genetics


Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition

Glatiramer acetate (Copaxone®; GA) is a non-biological complex drug for multiple sclerosis. GA modulated thousands of genes in genome-wide expression studies conducted in THP-1 cells and mouse splenocytes. Comparing GA…

Journal: Journal of Neuroimmunology


Page 1 of 2